Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | AKT1 | P31749 | 7/20 | 0.42 |
| ▸ | PARP1 | P09874 | 4/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 3/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30455937 | 0.91 | KIT (0.49) | KITPARP1SCD5TNKSTNKS2 | |
| SCHEMBL25225988 | 0.91 | KIT (0.49) | KITPARP1SCD5TNKSTNKS2 | |
| SCHEMBL30405752 | 0.90 | KIT (0.41) | KITAKT1PARP1MAP4K4SCD5 | |
| SCHEMBL25224723 | 0.90 | KIT (0.41) | KITAKT1PARP1MAP4K4SCD5 | |
| SCHEMBL31027420 | 0.89 | KIT (0.44) | KITAKT1PARP1MAP4K4TNKS | |
| SCHEMBL25280892 | 0.87 | KIT (0.44) | KITAKT1PARP1MAP4K4SCD5 | |
| SCHEMBL30405237 | 0.87 | KIT (0.44) | KITAKT1PARP1MAP4K4SCD5 | |
| SCHEMBL25437390 | 0.86 | KIT (0.51) | KITPARP1TNKSTNKS2CYP11B2 | |
| SCHEMBL30406053 | 0.86 | KIT (0.51) | KITPARP1TNKSTNKS2CYP11B2 | |
| SCHEMBL25221481 | 0.84 | KIT (0.39) | KITAKT1PARP1MAP4K4SCD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | BALA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| EP-4444313-A1 | INHIBITORS OF MENIN-MLL INTERACTION | Bala Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2023107687-A1 | INHIBITORS OF MENIN-MLL INTERACTION | BALA THERAPEUTICS, INC. (US) | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163061-A1 | INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, BMI1 | KIT 1067/4885AKT1 587/4885PARP1 330/4885 |
| US-20250066358-A1 | Inhibitors of Menin-MLL Interaction | MLLT1, MEN1, BMI1 | KIT 1067/4885AKT1 587/4885PARP1 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.